There are four dementia-specific medications approved in Australia – donepezil, galantamine, rivastigmine, and memantine.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials for ...

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BIIB) announced upcoming data presentations and programming at ...

Then in 1890, Emil von Behring made the remarkable discovery that serum derived from the blood of horses injected with ...

For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...

A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending ...

U.K. regulators will reportedly recommend the NHS not cover Eli Lilly’s (LLY) donanemab for the treatment of early ...

Key Presentations and Symposia: Transitioning from Clinical Trial to Clinical Practice for Long-Term Lecanemab Treatment in Early Alzheimer's Disease: Perspectives from an Alzheimer's Disease ...

Donanemab is a targeted antibody drug which slows down the early stages of Alzheimer’s. The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in ...

The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare ...